Adaptive Biotechnologies Corp (ADPT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.70B
Last updated: Nov 17, 2026 at 4:33 PM ET
Adaptive Biotechnologies Corp (ADPT) Stock Chart
Adaptive Biotechnologies (ADPT) has a latest price of $28.49 on Nov 17, 2026, 11.5% below its 52-week high of $32.21. Its price rose 102.1% over the past 12 months. The month-end price fell 20.3% over the 5 years through Oct 2026, a compound annual decline of 4.4%.
Price Chart
From Jun 2019 to Oct 2026, its highest month-end close was $59.13 in Dec 2020 and its lowest $2.62 in Apr 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ADPT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ADPT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 11.8%, and over 6 months it rose 119.8%. The month-end price rose 500.0% over the 3 years through Oct 2026, a compound annual rate of 81.7%.
| Period | Change |
|---|---|
| 1 month | +19.0% |
| 3 months | +11.8% |
| 6 months | +119.8% |
| 12 months | +102.1% |
| 12 months, with dividends | +102.1% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +500.0% | +81.7% |
| 5 years | -20.3% | -4.4% |
Price by Year
Its best calendar year was 2025, when the price rose 170.9%, and its weakest was 2022, when it fell 72.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $26.64 | +64.0% |
| 2025 | $16.24 | +170.9% |
| 2024 | $6.00 | +22.3% |
| 2023 | $4.90 | -35.9% |
| 2022 | $7.64 | -72.8% |
| 2021 | $28.06 | -52.5% |
| 2020 | $59.13 | +97.6% |
Trading Range
The price is 5.3% above its 50-day average of $27.06 and 41.1% above its 200-day average of $20.19.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $28.49 | |
| 52-week high | $32.21 | -11.5% |
| 52-week low | $12.00 | +137.4% |
| 50-day average | $27.06 | +5.3% |
| 200-day average | $20.19 | +41.1% |
Price Risk
Over 3 years, its largest fall from a peak was 56.2%.
| Measure | Value |
|---|---|
| 1-year beta | 1.53 |
| Largest fall, 1 year | -39.3% |
| Largest fall, 3 years | -56.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ADPT
What is ADPT's 1-year price change?
Adaptive Biotechnologies's price rose 102.1% over the past 12 months. With dividends included, the 12-month total return was 102.1%.
What is ADPT's 5-year price change?
Adaptive Biotechnologies's month-end price fell 20.3% over the 5 years through Oct 2026, a compound annual decline of 4.4%. These figures leave out dividends.
What is ADPT's 52-week high and low?
Adaptive Biotechnologies's 52-week high is $32.21 and its 52-week low is $12.00. Its latest price of $28.49 on Nov 17, 2026 is 11.5% below the high.
What is ADPT's beta?
Adaptive Biotechnologies's 1-year beta against the S&P 500 is 1.53, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 39.3%.
Is the ADPT chart free?
Yes. Advanced Charting for ADPT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ADPT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts